Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2021

08.10.2020 | Epidemiology

Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database

verfasst von: Hannah Grace Abraham, Yaoxuan Xia, Bhramar Mukherjee, Sofia Diana Merajver

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Inflammatory breast cancer (IBC) is an aggressive variant characterized by erythema, edema, and “peau d’orange” of the skin progressing within 6 months. We assessed the incidence and survival of IBC in the US over four decades.

Methods

Using SEER*Stat, a case list of IBC patients diagnosed between 1973 and 2015 (n = 29,718) was extracted from SEER 18 registries by using a combination of morphology, stage, and extent of disease criteria. M1 and M0 patients were included. Age-adjusted incidence rates, relative survival rates, and mean survival time were calculated. Significance was determined as non-overlapping 95% confidence intervals.

Results

The overall incidence of IBC from 1973 to 2015 is 2.76 (2.73, 2.79) cases per 100,000 people, with white patients having an incidence rate of 2.63 (2.60, 2.67), black patients 4.52 (4.39, 4.65), and patients of other race 1.84 (1.76, 1.93). The overall IBC relative 5-year survival rate is 40.5% (39.0%, 42.0%), 42.5% (40.7%, 44.3%), and 29.9% (26.6%, 33.3%) for white patients and black patients, respectively. Patients diagnosed in 1978–1982 have a mean survival time of 62.3 (52.0, 72.6) months, while those diagnosed in 2008–2012 have mean survival time of 99.4 (96.4, 102.4) months. There is no significant difference in survival time between T4D patients and patients with other T staging and extent of disease coding consistent with clinical IBC presentation.

Conclusions

IBC survival has increased over four decades. Despite the improvement in survival for all racial groups, a persistent survival disparity that has not narrowed over two decades remains between white and black patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372CrossRef Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372CrossRef
9.
Zurück zum Zitat Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74:291–297PubMed Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst 74:291–297PubMed
13.
Zurück zum Zitat Kaye DH, D. a Freedman, (2011) Reference guide on statistics. In: Kaye DH, Freedman DA (eds) Reference manual on science evidence, 3rd edn. The National Academies Press, Washington D.C, p 211 Kaye DH, D. a Freedman, (2011) Reference guide on statistics. In: Kaye DH, Freedman DA (eds) Reference manual on science evidence, 3rd edn. The National Academies Press, Washington D.C, p 211
14.
Zurück zum Zitat Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10. End results evaluation section. Bethesda, MD Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10. End results evaluation section. Bethesda, MD
15.
Zurück zum Zitat M. Greenwood (1926) A report on the natural duration of cancer. Reports on public health and medical subjects. Ministry of Health, London H M S O. M. Greenwood (1926) A report on the natural duration of cancer. Reports on public health and medical subjects. Ministry of Health, London H M S O.
16.
Zurück zum Zitat Brenner H, Gefeller O (1996) An alternative approach to monitoring cancer patient survival. Cancer 78:2004–2010CrossRef Brenner H, Gefeller O (1996) An alternative approach to monitoring cancer patient survival. Cancer 78:2004–2010CrossRef
17.
Zurück zum Zitat Efron B (1979) Bootstrap methods another look at the Jackknife. In: Kotz S, Johnson NL (eds) Breakthroughs in statistics. Series in statistics (Perspectives in statistics). Springer, New York, pp 569–593 Efron B (1979) Bootstrap methods another look at the Jackknife. In: Kotz S, Johnson NL (eds) Breakthroughs in statistics. Series in statistics (Perspectives in statistics). Springer, New York, pp 569–593
20.
Zurück zum Zitat Noone A et al (2017) SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda, MD Noone A et al (2017) SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda, MD
21.
Zurück zum Zitat DeSantis C, Miller K, Sauer AG, Jemal A, Siegel R (2019) Cancer statistics for African Americans, 2019. CA Cancer J Clin 69(3):211–233CrossRef DeSantis C, Miller K, Sauer AG, Jemal A, Siegel R (2019) Cancer statistics for African Americans, 2019. CA Cancer J Clin 69(3):211–233CrossRef
22.
Zurück zum Zitat DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRef DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRef
Metadaten
Titel
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
verfasst von
Hannah Grace Abraham
Yaoxuan Xia
Bhramar Mukherjee
Sofia Diana Merajver
Publikationsdatum
08.10.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05938-2

Weitere Artikel der Ausgabe 1/2021

Breast Cancer Research and Treatment 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.